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Summary
Malignant melanoma is increasing in frequency at a rapid rate in the United States. Metastatic disease is chemores-
istant with DTIC considered the most active single agent. CI-980 is a synthetic mitotic inhibitor that blocks the
assembly of tubulin and microtubules. It has shown cytotoxic activity against a broad spectrum of murine and hu-
man tumor cell tines. CI-980 can cross the blood brain barrier, is effective when given orally or parenterally, and is
active against multidrug resistant cell lines overexpressing P-glycoprotein. In this trial, patients with disseminated
melanoma with measurable disease, SWOG performance status of 0–1, no prior chemotherapy or immunotherapy
for metastatic disease, and adequate hepatic and renal function, were enrolled. Treatment with CI-980 was given
by 72 h continuous IV infusion at a dose of 4.5 mg/m2/day, days 1–3 every 21 days. Twenty-four patients were
registered on this study with no patients ineligible. They ranged in age from 33–78 with performance status of
0 in 15 patients and 1 in 9 patients. Nineteen patients had visceral disease with 12 having liver involvement.
There were no confirmed responses. The overall response rate was 0% (95% CI 0% –14%). The median overall
survival is eleven months (95% CI 4–14 months). The most common toxicities were hematologic and consisted
of leukopenia/granulocytopenia and anemia, with nausea/vomiting and malaise/fatigue/weakness also frequent.
CI-980 administered at this dose and schedule has insufficient activity in the treatment of disseminated malignant
melanoma to warrant further investigation.
Introduction
Malignant melanoma is a common problem in the
United States with almost 40,000 new cases and over
7000 deaths annually [1]. Its frequency is increasing,
perhaps due to increased recreational exposure to sun-
light, with a doubling of the death rate in the last 35
years and increases of approximately 5% per year in
the older Caucasian population [1]. Chemotherapy is
relatively ineffective for metastatic disease with only 2
out of 30 drugs tested, DTIC and nitrosourea, produ-
cing response rates of 10% or better [1]. Complete re-
sponses are rare. There is no convincing evidence that
combination chemotherapy is significantly better than
DTIC alone [1,2]. CI-980, (NSC 635370 [ethyl (S)-(5-
amino-1,2-dihydro-2-methyl-3-phenylpyrido (3, 4-b)
pyrazin–7-yl) carbamate 2-hydroxyethane sulfonate])
is a synthetic mitotic inhibitor which binds to the
colchicine binding site on tubulin but at a site dis-
tinct from that of the vinca alkaloids, inhibiting the
assembly of purified tubulin and microtubules [3–5].
This disrupts structural components of the cell and
blocks formation of the mitotic spindle. Treated cells
accumulate in M phase of the cell cycle and die.
CI-980 has demonstrated profound cytotoxic activ-
ity against a broad spectrum of both murine and human
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tumors in vivo, including P388 leukemia, L1210 leuk-
emia, B16 melanoma, M5076 sarcoma, mammary
adenocarcinoma 16c, and colon adenocarcinoma 36,
11a, and 26 [6,7,8]. It is twice as potent as vincristine
against P388 leukemia [6]. Multidrug resistance due to
P-glycoprotein overexpression does not seem to con-
fer resistance to CI-980 in contrast to other agents
[6,7,8]. CI-980 showed activity in intracranial tumor
implants, and tissue distribution studies confirmed that
it could cross the blood brain barrier, a characteristic
potentially useful in melanoma patients. It retained full
activity when given PO as well as IM or IV [6,7].
Phase I trials of the drug resulted in severe CNS
toxicity consisting of loss of consciousness, confu-
sion, tremors and coma when it was given by 1 to 24
h infusion [9]. However when given over 72 h, CNS
effects were mild to moderate with leukopenia the
principal dose limiting toxicity [9]. This trial reports
the effects of CI 980 in previously untreated patients
with disseminated melanoma when given as a 72 h
infusion.
Materials and methods
Patient population. All patients were required to have
a histologically proven diagnosis of malignant melan-
oma that was Stage IV and not surgically curable,
with bidimensionally measurable disease. Patients had
to have no evidence of brain metastases by CT or
MRI; if they had a history of brain metastasis, they
had to be resected completely free of disease fol-
lowed by a course of whole brain radiation therapy.
They had to have a Southwest Oncology Group per-
formance status of 0 or 1 (≥70 Karnofsky), thus
ambulatory and able to carry out light work. Patients
may have received prior biologic or immunothera-
peutic regimens given in an adjuvant fashion, but
no adjuvant chemotherapy and no prior chemother-
apy or immunotherapy for metastatic disease. Prior
surgery, hormonal therapy or isolated limb perfusion
was allowed provided it was completed at least 28
days before registration and patients had recovered
from all adverse effects. Prior radiation therapy was
allowed provided there was objective evidence of pro-
gression of disease or measurable unirradiated disease
sites. Patients had to have a pretreatment granulocyte
count of ≥1500 cells/µl, a platelet count ≥100,000
cells/µl, and hemoglobin ≥10 gm/dl. Serum creatine
and serum bilirubin had to be less than or equal to the
institutional upper limit of normal and serum glutamic
– oxaloacetic transaminase level (SGOT) had to be
≤2.5 times the institutional upper limit of normal or
≤5 times the institutional upper limit of normal if the
liver was involved by tumor. Patients with other ser-
ious illnesses, active infections, and those requiring
therapy with other investigational drugs, corticoster-
oids, or antibiotics were not eligible. Patients with
AIDS or known to be human immunodeficiency virus
antibody seropositive as well as pregnant or nursing
women were not eligible. Patients with a second ma-
lignancy were not eligible unless it was an adequately
treated basal or squamous cell skin cancer, in situ
cervical cancer, adequately treated stage I or II can-
cer from which the patient was currently disease-free,
or any other cancer for which the patient had been
disease-free for at least 5 years. Women and men of
reproductive potential had to agree to use an effective
contraceptive method. No type of concomitant therapy
for the patient’s melanoma was allowed.
CI-980. CI-980 was supplied by the National Can-
cer Institute as a sterile lyophilized powder in 6 ml
amber glass vials containing 10 mg CI-980 base equiv-
alent. It was reconstituted with 5 ml of Water for In-
jection, USP, resulting in a concentration of 2 mg/ml.
It was further diluted in D5W for IV infusion. Solu-
tions of CI-980 could only be administered through
peripheral IV lines (not recommended due to the risk
of phlebitis) or through subclavian central venous
catheters made of silicone.
Treatment plan. CI-980 was given by a 72 h con-
tinuous IV infusion at a dose of 4.5 mg/m2/day, days
1–3 of each 21 day treatment cycle. Inpatient ad-
ministration was required during the first cycle and
was optional thereafter. Pretreatment with antiemetics
capable of preventing mild to moderate nausea and
vomiting was recommended. Because of sterility and
stability considerations, each prepared dose of drug
was infused over 24 h after which a fresh dose was
started. Dose reduction of 25% was required for the
development of grade 2 or higher disorientation for
greater than 24 h, or grade 3 or higher other neuro-
toxicity. If after 2 dose reductions, the patient again
developed a similar level of neurotoxicity, they were
removed from treatment. Weekly CBC and platelet
counts were required during the first 3 week cycle
and if grade 3 or 4 levels of granulocytopenia or
thrombocytopenia were seen, then weekly counts were
required in all subsequent cycles. At a minimum, a
CBC was required the week of treatment and on day 8
of each cycle. A grade 4 level of absolute granulocyte
count (<500 cells/µl) at any time during treatment
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required a 25% dose reduction from baseline in sub-
sequent cycles and allowed optional use of G-CSF.
Once a dose reduction occurred for hematologic tox-
icity, there was no re-escalation of dose allowed, even
if G-CSF was used. If after 2 dose reductions grade 4
toxicity recurred, the patient was removed from treat-
ment. Other toxicities of grade 4 level required similar
dose reductions and treatment discontinuation.
Definition of response. Standard SWOG response
criteria were used to define the antitumor effects that
were observed. A complete response required the dis-
appearance of all measurable and evaluable disease in
all disease sites including normalization of abnormal
disease-related laboratory values and disease-related
symptoms with no new lesions. A partial response
required ≥50% decrease in the sum of the products
of the perpendicular diameters of all measurable le-
sions, with no new lesions or progression of evaluable
disease with all measurable and evaluable lesions and
sites assessed. Progressive disease was defined as (a)
a 50% increase or an increase of 10 cm2 (whichever
is smaller) in the sum of the products of measur-
able lesions over the smallest sum observed or clear
worsening of any evaluable disease, or (b) the appear-
ance of any new lesion or the reappearance of any
lesion that had disappeared, or (c) failure to return for
evaluation due to deteriorating condition (unless de-
terioration was clearly unrelated to the cancer). Stable
disease was disease that did not meet the criteria for
either a complete or partial response or progression.
Tumor assessment was requested at the end of every
two cycles. After first documentation of a complete
or partial response, a second assessment was required
after a minimum of 3 weeks to confirm the response.
Results
Patient population. Twenty four patients from 17 dif-
ferent institutions were registered on this study. No
patients were ineligible. The characteristics of all 24
eligible patients are listed in Table 1. They ranged
in age from 33–78 and 12 (50%) were male. Fifteen
(63%) had a performance status of 0 while 9 (38%)
had a performance status of 1. Seven (29%) had prior
adjuvant biologic therapy and 3 (13%) prior radiation
treatment. Nineteen patients (79%) were M1b, thus
having some site of visceral metastases. The liver was
involved with tumor in 12 patients (50%). One patient
had had previous resection and radiation of a brain
lesion.
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Response and survival. Response data are listed in
Table 2. All 24 eligible patients were evaluated for
response. There were no confirmed responses. There
was one unconfirmed response in a patient with a liver
lesion that decreased by more than 50% at first eval-
uation 6 weeks after beginning therapy, but new liver
and lung lesions developed by the next evaluation 4
weeks later. Because of the transient, unconfirmed
nature of the response, this patient is considered to
be a non-responder. Hence, the overall response rate
was 0% with a 95% confidence interval of 0 to 14%.
Twenty-one patients came off treatment because of
progression, one came off because of toxicity, one
refused treatment unrelated to toxicity, and one pa-
tient was off treatment because of death due to disease
related causes prior to first assessment. There were
no major protocol deviations. Twenty-two of the 24
patients have died. The median overall survival is 11
months with a 95% confidence interval of 4 months to
14 months.
Toxicity. All 24 patients were evaluated for toxicity
(see Table 3). The most common toxicities were hem-
atologic and consisted of leukopenia/granulocytopenia
(67%) and anemia (58%). Thrombocytopenia was not
as prominent. Malaise/fatigue/weakness was also fre-
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Table 2. Response – N = 24
Number Percent
Complete response 0 0%
Partial response 0 0%
Unconfirmed response 1 4%
Stable/no response 7 29%
Increasing disease 16 67%
Total 24 100%
Table 3. Toxicity – N = 24
Any grade Grade Grade
Toxicity No. % 3 No. 4 No.
1. Leukopenia/granulocytopenia 16 67% 5 5
2. Anemia 14 58% 1 0
3. Nausea/vomiting 12 50% 2 0
4. Malaise/fatigue/weakness 10 42% 2 0
5. Local/phlebitis/thrombosis 6 25% 1 0
6. Fever without infection 6 25% 0 0
7. Neurologic 5 21% 0 0
8. Thrombocytopenia 4 17% 1 0
9. Lymphopenia 4 17% 0 0
10. GI-other 4 17% 0 0
11. Pain 3 13% 0 0
12. Weight gain/loss 3 13% 0 0
13. Infection 2 8% 0 0
14. Respiratory 2 8% 0 0
15. Cardiac 1 4% 0 0
16. Diarrhea 1 4% 0 0
17. Miscellaneous 8 33% 0 1
quent. Nausea and vomiting was occasionally severe
but mostly controlled. The grade 4 miscellaneous
toxicity was hypoxia from probable oversedation.
Discussion
CI-890 is a very potent mitotic and microtubule inhib-
itor with in vitro activity superior to vincristine that is
fully active against vincristine-resistant tumors [10]. It
is widely and uniformly distributed in mice thus indic-
ating that it has the ability to cross physiologic barriers
and penetrate tumor masses [6]. Because of this it is
fully active whether given IV, IM, or PO, making it
a suitable drug for outpatient therapy [9]. Phase I tri-
als have shown that in the doses and schedule used
here, blood levels are achieved which show activity
against most human leukemias and solid tumors in
vitro [9]. In addition, the 72 h infusion schedule pro-
duces prolonged exposure to drug which also enhances
cytotoxicity [9].
Thus this phase II trial in patients with dissemin-
ated melanoma was undertaken with hope that there
might be significant benefit to patients. Unfortunately,
no beneficial antitumor actively was found, and further
testing of CI-980 in melanoma patients at this dose and
schedule is not recommended. A similar lack of activ-
ity was seen in phase II trials of CI-980 in colorectal
cancer and soft tissue sarcoma patients in which it
was given by the same dose and schedule used here
[11,12]. One out of sixteen patients with platinum re-
fractory ovarian cancer responded to CI-980 given as
in this trial [13].
It is possible that alternative dosing schedules,
such as infusions of longer duration, might be useful.
In addition, CI-980 has shown synergy with cisplatin
and BCNU in tumor model systems [14]. Thus tri-
als of combinations with other agents or evaluation
in other tumor types such as leukemia and lymphoma
may ultimately prove worthy of investigation.
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